about
Safety and efficacy of azacitidine in myelodysplastic syndromesRobotic liquid handling and automation in epigeneticsEpigenetics advancing personalized nanomedicine in cancer therapyMolecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTsIdentification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugsEpigenetics and human disease: translating basic biology into clinical applicationsChromatin modifications as therapeutic targets in MLL-rearranged leukemia.Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine.Differential regulation of the dioxin-induced Cyp1a1 and Cyp1b1 genes in mouse hepatoma and fibroblast cell lines.Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategiesDemethylating agents in myeloid malignancies.A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic.Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice.Aberrant promoter CpG methylation and its translational applications in breast cancer.Azacitidine for the treatment of myelodysplastic syndrome.Epigenome manipulation as a pathway to new natural product scaffolds and their congeners.Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity.The application of delivery systems for DNA methyltransferase inhibitors.Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor.Epigenetic regulation of mmp-9 gene expression.Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.Novel immune modulators used in hematology: impact on NK cellsHistone mimics: digging down under.The discovery of medicines for rare diseasesHypomethylation reduced the aggressive potential of human malignant mesothelioma cells.The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines.Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells.Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer.Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.Chalcogenozidovudine Derivatives With Antitumor Activity: Comparative Toxicities in Cultured Human Mononuclear Cells.Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: insights from enzymatic and molecular modeling studies.Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.
P2860
Q24596561-FFB065CA-16BD-48D0-8451-60ABB25F0F0DQ26822439-5FE1D687-877C-47A0-9823-5A1DF1A67602Q27010637-38C97872-1B86-4C13-8876-685B0A473038Q28487027-CCCF1FCB-2E91-41AE-8F7F-26B9B0229608Q28533669-EB5380FF-0A3D-4FC4-96BF-4A25AB7A2F8BQ28768502-009CA90C-F778-49D4-9A67-0BE691CD4772Q33666543-4EC18E23-1747-4D8E-B9E0-65CA8138E918Q33680168-CAF78C8D-46EE-4BF9-A1D2-B8012E067D84Q33729483-82526623-63D7-4420-A51F-3167E8F92C6BQ33798412-5921615E-E1FB-434C-A44D-AD8AB4FCFF55Q34768789-0D1E2F25-8E0F-4D69-8D87-42B975CD5381Q34847863-2976FF3E-C432-423C-82D3-D4881886EAFCQ35206418-5C96B283-341C-41C2-9371-0687B52BFF0BQ35492725-30CF073F-42F9-4C01-9CF4-A4E63D711217Q35687461-8A29B451-BC82-4056-9966-74343DF782E9Q36345789-263622EB-157B-410B-BF5C-45FBAAC1BCCDQ36430196-F4285D10-9B41-4B6B-9108-BBD4C36D6912Q36445921-9F22C259-416F-4C61-B174-37B8783D5934Q37220262-F7E2ABB4-8484-4527-9202-D3EBF3A649D0Q37354053-7D15CCAB-9F45-4529-B5A9-9E8AD6B0A930Q37546018-5A3F49F7-3F44-44F8-811D-9731B0030695Q37660083-9CC62A8C-4135-4BAF-9ECF-6608BD098AEBQ37696099-2C971597-E72E-47C5-9AA2-1C02BE7A3510Q37911496-DFAB83AD-D600-41A8-87A1-B754834B5A98Q38011287-3A5F5EA5-BBAF-4F29-BB5E-AD8958E73ABDQ38062851-272C9382-36FE-4DC8-AA9A-114E21206EAAQ38071897-353B1491-6193-4AD6-9AD8-0C6D86DE7DFDQ38073760-3720DD2F-C7B9-4B34-9ED3-15B75DECC123Q38223397-8037ABBE-1035-42AC-8E2D-FE3606EB29EDQ39152821-91813A5C-5CC9-4B09-897F-735CFFC14D7EQ39179225-5305E2A4-37C8-4678-942C-E0230D9D154AQ44143302-2B2F9B2E-2B91-4932-9245-B3F9290394DEQ44152775-15BDAD11-F932-4280-8F47-3BC425C6D0D6Q45814721-6562CA8E-9315-43FC-8514-A83899926582Q45873027-E1E24ACB-F218-44C3-90B8-E545F62B6E2EQ46284143-C7F6DBDE-92A5-4865-890E-22019FCC01F3Q47259985-54956516-5399-4960-82E5-DD00BF165D26Q48180430-57EE06D1-697A-4184-A7DF-01E7A19AFD27Q48973690-F547E6E8-9A36-438D-B22C-9984C3C04928Q51725692-E072790C-43B3-4FD1-8133-F7E4FA7215DE
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Azacitidine.
@ast
Azacitidine.
@en
Azacitidine.
@nl
type
label
Azacitidine.
@ast
Azacitidine.
@en
Azacitidine.
@nl
prefLabel
Azacitidine.
@ast
Azacitidine.
@en
Azacitidine.
@nl
P2860
P356
P1476
Azacitidine
@en
P2093
Hagop M Kantarjian
P2860
P2888
P304
P356
10.1038/NRD1698
P577
2005-04-01T00:00:00Z